| Autor: |
Iwabuchi S; Department of Molecular Pathophysiology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Wakayama 641-0011, Japan., Takahashi K; Department of Human Pathology, Graduate School of Medicine, Kanazawa University, Ishikawa, Kanazawa 920-0934, Japan., Kawaguchi K; Department of Gastroenterology, Kanazawa University Hospital, Ishikawa, Kanazawa 920-0934, Japan., Nagatsu A; Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Hokkaido, Sapporo 060-8648, Japan., Imafuku T; Department of Molecular Pathophysiology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Wakayama 641-0011, Japan., Shichino S; Division of Molecular Regulation of Inflammatory and Immune Disease, Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Noda 278-8510, Japan., Matsushima K; Division of Molecular Regulation of Inflammatory and Immune Disease, Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Noda 278-8510, Japan., Taketomi A; Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Hokkaido, Sapporo 060-8648, Japan., Honda M; Department of Gastroenterology, Kanazawa University Hospital, Ishikawa, Kanazawa 920-0934, Japan., Hashimoto S; Department of Molecular Pathophysiology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Wakayama 641-0011, Japan. |
| Abstrakt: |
Although benign hepatocellular adenomas (HCA) are very rare, recent observations have shown their occurrence in patients with diabetes mellitus. Consequently, most of these cases are treated by resection due to concerns regarding their potential progression to hepatocarcinoma (HCC). This decision is largely driven by the limited number of studies on HCC subtyping and the lack of molecular and biological insights into the carcinogenic potential of benign tumors. This study aimed to comprehensively investigate the subtype classification of HCA and to compare and analyze gene expression profiling between HCA and HCC tissues. One fresh inflammatory HCA (I-HCA), three non-B non-C HCCs, two hepatitis B virus-HCCs, and one normal liver tissue sample were subjected to single-cell RNA sequencing (scRNA-seq). Comparative analysis of scRNA-seq among different tissues showed that phospholipase A2 group IIA ( PLA2G2A ) mRNA was specifically expressed in I-HCA, following RNA-seq analysis in formalin-fixed paraffin-embedded tissues from other HCAs. Immunohistochemistry using the PLA2G2A antibody in these tissues indicated that the positive reaction was mainly observed in hepatocytes of I-HCAs and stromal cells surrounding the tumor tissue in HCC were also stained. According to a clinical database, PLA2G2A expression in HCC does not correlate with poor prognosis. This finding may potentially help develop a new definition for I-HCA, resulting in a significant clinical contribution, but it requires validation with other fresh HCA samples. |
